Ua wehe ʻo Flagship Pioneering i kēia lā ʻo Vesalius Therapeutics, kahi hui i kālele ʻia i ka wehewehe hou ʻana i ka ʻike a me ka mālama ʻana i nā maʻi e alakaʻi ai i ka 90% o ka maʻi kanaka. Ua hāʻawi mua ʻo Flagship i $75 miliona no ke kākoʻo ʻana i ka hoʻomohala ʻana o ke kahua ʻo Vesalius a me ka pipeline mua o nā lāʻau lapaʻau hou. ʻO Christopher Austin, MD, ka mea i lawelawe ma mua ma ke ʻano he Luna Hoʻokumu o ka National Center for Advancing Translational Science (NCATS) ma ka National Institutes of Health (NIH), e alakaʻi i ka hui ma ke ʻano he Luna Nui. Ua komo ʻo Kauka Austin i ka Flagship i Malaki o 2021 ma ke ʻano he Luna Nui-Partner.

"ʻAʻole i neʻe koke ka holomua i ka mālama ʻana i kekahi o nā maʻi ʻino loa o ka lehulehu no ka mea ʻaʻole i wehewehe pololei kā mākou ʻoihana i ka pilikia. Ma Flagship, ua ʻike mākou no ka hoʻoponopono ʻana i kēia mau kūlana pono mākou e noʻonoʻo ʻokoʻa, "wahi a Doug Cole, MD, Managing Partner ma Flagship Pioneering, co-founder o Vesalius, a me ka luna o kāna Papa Hoʻokele. "Ua hoʻokumu ʻia ʻo Vesalius e hoʻoponopono hou i ke ʻano o kā mākou ʻike, ʻike, a mālama i nā maʻi maʻamau i mālama ʻole ʻia e ka biotechnology. Ke manaʻoʻiʻo nei mākou e loaʻa ka hopena hoʻololi i kā mākou hiki ke mālama i nā maʻi e hoʻoulu ai i ka kanaiwa pakeneka o ka ʻeha a me ka make ma ka honua.

I kēia manawa, nui nā maʻi e pili ana i nā miliona o ka poʻe maʻi ma ka honua holoʻokoʻa loaʻa kahi maʻi hoʻokahi (e laʻa, ka maʻi diabetes) e hoʻopuni ana i nā maʻi like ʻole, e pili ana kēlā me kēia pūʻulu o nā maʻi me nā kumu kūlohelohe ʻokoʻa. ʻO kēia ka hopena pinepine i nā hōʻailona kūʻokoʻa, i alakaʻi ʻia e nā abnormalities i loko o nā kaapuni genetic i ʻokoʻa mai nā mea hoʻokele i loaʻa i nā hui ʻē aʻe - ʻo ia hoʻi, ʻo nā mea maʻi e kaʻana like i kēia lā i kahi hōʻailona, ʻoiaʻiʻo, ʻaʻole nā mea āpau i loaʻa i ka maʻi like.

Hana ʻo Vesalius 'DIAMOND platform e like me kahi prism e hoʻokaʻawale i nā poʻe maʻi i loko o nā pūʻulu therapeutically koʻikoʻi me ka hoʻohana ʻana i ka naʻauao a me ke aʻo ʻana i ka mīkini e hoʻomālamalama i ka biology i lalo o ka hōʻike lapaʻau. Hoʻokumu ʻo DIAMOND i nā ʻōnaehana hoʻokolohua ponoʻī i hoʻohana ʻia e nānā a hōʻike i nā moho lāʻau lapaʻau e hoʻihoʻi i kēia mau kaapuni i ka hana olakino. E hōʻike ana kēia ala i nā ala hou e hoʻomohala i nā lāʻau lapaʻau no nā maʻi intractable ma mua.

Ua ʻōlelo ʻo Kauka Austin, "ʻAʻole monolithic nā maʻi maʻamau, he hui maoli nō ia o nā maʻi like ʻole genetically a biologically e pili ana i ka poʻe maʻi. ʻO kā mākou papa DIAMOND e hiki ai iā mākou ke wehewehe i kēia mau pūʻulu o nā maʻi a hoʻomaopopo i kā lākou biology kaʻana i ka home ma ka therapeutic kūpono no ka hui kūpono o nā maʻi. Ma ka hoʻomaʻemaʻe ʻana i nā pūʻulu maʻi e kā lākou mau hōʻailona like, genetics, a me ka biology, manaʻo mākou hiki iā mākou ke hoʻomaikaʻi i nā manawa kūpono o ka hoʻomohala ʻana i nā lāʻau lapaʻau no nā maʻi maʻamau. Eia kekahi, me ka hoʻohana ʻana i nā hiʻohiʻona hoʻokolohua e pili ana i ke kelepona kanaka, ʻoi aku ka maikaʻi o kā mākou kahua i ka hoʻāʻo ʻana i nā koho therapeutic hou e hoʻomaikaʻi hope ai i nā ola maʻi.

"Pono mākou i nā manaʻo nui a me nā manaʻo wiwo ʻole inā mākou e hoʻomohala i nā hopena hopena no kekahi o nā maʻi kaumaha loa o ke kaiāulu, a ʻo ka ʻike o Chris ma kahi kokoke i hoʻokahi ʻumi makahiki ma ke ʻano he luna hoʻokumu o ka National Center for Advancing Translational Science ma NIH. kūpono no ka misionari a Vesalius, "wahi a Noubar Afeyan, Ph.D., Hoʻokumu a Luna Hoʻokele o Flagship Pioneering. “ʻO kāna ʻike hoʻolālā i alakaʻi i ka holomua i ka ʻepekema unuhi i hoʻolalelale nui i ka hoʻomohala ʻana i kekahi mau lāʻau lapaʻau hoʻololi. Loaʻa iā ia ka ʻike hohonu i ka ʻike ʻana i ka genetic target ma o kāna hana me ka National Human Genome Research Institute a ma Merck ʻo ia ka hoʻokūkū kūpono loa no ka hoʻokūkū nui e hiki mai ana i ka mālama olakino.

Ua holomua nui ʻo Vesalius i ka ʻike ʻana i nā kaapuni genetic i loko o nā subpopulations o nā maʻi i nā maʻi paʻakikī e mālama ʻia, e hāʻawi ana i ka hōʻoia-o-manaʻo no kona hoʻokokoke ʻana, a me ka wehe ʻana i ka puka i nā ʻano lāʻau lapaʻau like ʻole. Manaʻo ka hui e hoʻolimalima ma mua o 200 poʻe i nā makahiki ʻelua e hiki mai ana e kākoʻo i ka holomua o kāna kahua a me nā papahana.

He aha e lawe ʻia mai kēia ʻatikala:

This often results in unique symptoms, which are driven by abnormalities in genetic circuits that differ from the drivers found in the other groups – meaning that patients who today share a diagnosis are, in fact, not all suffering from the same disease.
Our DIAMOND platform enables us to elucidate these defined groups of patients and understand their shared biology to home in on the right therapeutic for the right group of patients.
He also has deep experience in genetic target discovery through his work with the National Human Genome Research Institute and at Merck that is the perfect match for the next great challenge in healthcare.